Sartorius AG

euro adhoc: Sartorius AG
quarterly or semiannual financial statement
Group sales revenue rose 10.2%; currency-adjusted, up 9.1%
EBITDA EBITDA improved 22.8% to EUR31.6 million
EBIT up 31.7% to EUR22.0 million / Earnings per share: EUR0.69, up fr

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc.   The issuer is responsible for the content of this announcement. --------------------------------------------------------------------------------@@end@@

19.07.2006

During the first half of fiscal 2006, sales revenue of the Sartorius Group rose 10.2% (currency-adjusted: +9.1%) to EUR257.1 million (previous year: EUR233.2 mn). In the Biotechnology Division, sales revenue climbed 12.4% (currency-adjusted: +11.2%) to EUR135.9 million (EUR120.9 mn); the Mechatronics Division achieved a gain in sales revenue of 7.9% (currency-adjusted: +6.8%) to EUR121.2 million (EUR112.3 mn). Up 6.9% (currency-adjusted: +5.6%), order intake also rose considerably to EUR261.3 million (EUR244.4 mn).

First-half earnings before interest, taxes, depreciation and amortization (EBITDA) surged 22.8% to EUR31.6 million (EUR25.7 mn). Earnings before interest and taxes (EBIT) soared 31.7% to EUR22.0 million (EUR16.7 mn); as a result, the EBIT margin increased from 7.2% to 8.6%. For the Biotechnology Division, EBIT rose from EUR9.6 million to EUR14.8 million, whereas for the Mechatronics Division, EBIT at EUR7.2 million (EUR7.1 mn) was approximately at the previous year’s level. Second-quarter earnings of the Mechatronics Division already include an above-average portion of the full-year costs budgeted for the expansion of company locations in Germany and China and for the new alignment of the sales organizations of Western European subsidiaries. Net profit for the period surged 53.3% to EUR11.7 million (EUR7.6 mn); earnings per share were EUR0.69 (EUR0.45). Despite the rise in capital expenditures, which approximately doubled compared with the year-earlier figure, net cash flow at EUR5.0 million (EUR7.2 mn) was positive.

The company is concretizing its goal of increasing full-year sales revenue by more than 5% and is striving to achieve sales revenue growth of about 7% on the basis of constant currencies. The target of achieving earnings before interest and taxes of approximately 10% of sales revenue is confirmed.

@@start.t2@@end of announcement                                                 euro adhoc 19.07.2006 07:11:31
--------------------------------------------------------------------------------@@end@@

ots Originaltext: Sartorius AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:
Andreas Wiederhold
Phone +49.551.308.1668
andreas.wiederhold@sartorius.com
www.sartorius.com

Branche: Biotechnology
ISIN:      DE0007165607
WKN:        716560
Index:    CDAX, Prime All Share, Technologie All Share
Börsen:  Frankfurter Wertpapierbörse / official dealing/prime standard
              Börse Berlin-Bremen / free trade
              Hamburger Wertpapierbörse / free trade
              Baden-Württembergische Wertpapierbörse / free trade
              Börse Düsseldorf / free trade
              Bayerische Börse / free trade
              Niedersächsische Börse zu Hannover / official dealing



Weitere Meldungen: Sartorius AG

Das könnte Sie auch interessieren: